Royal Bank of Canada’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-5,131
| Closed | -$369K | – | 7605 |
|
|
2025
Q4 | $369K | Sell |
5,131
-311,328
| -98% | -$20.1M | ﹤0.01% | 4384 |
|
|
2025
Q3 | $13.8M | Sell |
316,459
-290,248
| -48% | -$11.7M | ﹤0.01% | 1930 |
|
|
2025
Q2 | $17.2M | Buy |
606,707
+562,403
| +1,269% | +$16.8M | ﹤0.01% | 1647 |
|
|
2025
Q1 | $1.31M | Buy |
44,304
+12,241
| +38% | +$381K | ﹤0.01% | 3264 |
|
|
2024
Q4 | $932K | Sell |
32,063
-19,519
| -38% | -$816K | ﹤0.01% | 3588 |
|
|
2024
Q3 | $2.37M | Buy |
51,582
+41,473
| +410% | +$1.8M | ﹤0.01% | 2862 |
|
|
2024
Q2 | $413K | Buy |
10,109
+6,970
| +222% | +$200K | ﹤0.01% | 4165 |
|
|
2024
Q1 | $80K | Sell |
3,139
-20,805
| -87% | -$326K | ﹤0.01% | 5316 |
|
|
2023
Q4 | $217K | Buy |
23,944
+11,856
| +98% | +$79.3K | ﹤0.01% | 5044 |
|
|
2023
Q3 | $77K | Buy |
12,088
+4,414
| +58% | +$38K | ﹤0.01% | 5546 |
|
|
2023
Q2 | $85K | Buy |
7,674
+3,280
| +75% | +$41.1K | ﹤0.01% | 5456 |
|
|
2023
Q1 | $67K | Sell |
4,394
-2,891
| -40% | -$63.6K | ﹤0.01% | 5463 |
|
|
2022
Q4 | $161K | Buy |
7,285
+6,043
| +487% | +$90.1K | ﹤0.01% | 5067 |
|
|
2022
Q3 | $20K | Buy |
1,242
+868
| +232% | +$16.6K | ﹤0.01% | 6147 |
|
|
2022
Q2 | $5K | Sell |
374
-2,438
| -87% | -$36.3K | ﹤0.01% | 6665 |
|
|
2022
Q1 | $52K | Sell |
2,812
-5,113
| -65% | -$86.9K | ﹤0.01% | 6066 |
|
|
2021
Q4 | $189K | Buy |
7,925
+135
| +2% | +$3.22K | ﹤0.01% | 5396 |
|
|
2021
Q3 | $192K | Buy |
7,790
+944
| +14% | +$20.5K | ﹤0.01% | 5214 |
|
|
2021
Q2 | $169K | Sell |
6,846
-277
| -4% | -$6.44K | ﹤0.01% | 5223 |
|
|
2021
Q1 | $155K | Buy |
7,123
+3,798
| +114% | +$93K | ﹤0.01% | 5137 |
|
|
2020
Q4 | $85K | Buy |
+3,325
| New | +$97K | ﹤0.01% | 5422 |
|
Other funds holding RNAM
Royal Bank of Canada's RNAM Position: Q1 2026 in Review
Royal Bank of Canada sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 5,131 shares — an estimated $369K sold.
Royal Bank of Canada first reported a position in RNAM in Q4 2020 and held it in 21 quarters. The position peaked at $17.2M in Q2 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Royal Bank of Canada reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Royal Bank of Canada sold 5,131 Avidity Biosciences shares in Q1 2026, an estimated $369K.
- Royal Bank of Canada first reported a position in Avidity Biosciences in Q4 2020 and held it in 21 quarters.
- Royal Bank of Canada's Avidity Biosciences position peaked at $17.2M in Q2 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.